Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Merger Agreement with BioCircuit filed for investor access, signaling a proposed strategic transaction.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Merger Agreement with BioCircuit filed for investor access, signaling a proposed strategic transaction
- Agreement language limits reliance on representations, warranties and covenants as factual descriptions
- Confidential disclosures allocate contractual risk and may qualify stated terms
- Investors should evaluate transaction details and subsequent disclosures rather than agreement language alone
Item 7.01 · Regulation FD Disclosure
- Corrected investor presentation furnished as Exhibit 99.2 under Regulation FD
- Amendment supersedes the previously furnished investor presentation
- Investors should rely on the corrected exhibit for company-disclosed presentation information
Item EX-99.1 · Exhibit EX-99.1
- Planned $200M cash acquisition of BioCircuit Technologies, subject to customary adjustments and closing conditions
- BioCircuit contributes ~$24M annualized Q2 2026 revenue, $11M 2025 revenue, ~80% gross margins, and $11M standalone EBITDA
- NerveTape is the first FDA-cleared sutureless nerve-repair device, expanding Axogen’s addressable market and reducing microsurgical skill requirements
- Deal expected accretive to revenue growth and adjusted EBITDA margins in Year 1 while Axogen remains free-cash-flow positive
- Substantially all equity-offering proceeds earmarked for consideration, fees, and expenses; closing expected Q4 2026 subject to convertible-note conversion and other conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.